In melanoma-bearing mice, tumor uptake of 99mTc-labeled CGCG-NDPMSH at 30 min postinjection was 6.52 %ID/g.
In plain wordsIn mice with melanoma, a radiolabeled NDP-MSH analog reached the tumor at 6.52 percent of the injected dose per gram.
- Peptide
- Melanotan I (afamelanotide)
- Outcome
- Not applicableTumor uptake of 99mTc-CGCG-NDPMSH at 30 min
- Study
mousen: not reported in source
melanoma-bearing mice- Outcome group
- Pharmacokinetics · Cancer
Measurements
- Tumor uptake
- 6.52 %ID/g
- 99mTc-CGCG-NDPMSH, 30 min
Source sentences
Tumor uptake of 99mTc-labeled CGCG- and MAG2-NDPMSH analogs at 30 min postinjection were 6.52 +/- 1.11 %ID/g and 4.17 +/- 1.34 %ID/g, respectively, resulting in a significantly higher tumor-to-blood uptake ratio than that of 125I-NDPMSH or a shorter alpha-MSH analog, 99mTc-CGCG-DPMSH.
1 context sentence(design, population, supporting numbers)
Radiolabeled alpha-melanocyte stimulating hormone (alpha-MSH) analogs were examined in melanoma-bearing mice to determine the effects of peptide length, structure, and radiometal chelation chemistry on tumor targeting and in vivo biodistribution.
In this study, Melanotan I (afamelanotide) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Melanotan I (afamelanotide).